Genetic engineering for xenotransplantation

Journal of Cardiac Surgery

Volumn 16, Issue 6, 2001, Pages 448-457

  Sandrin, Mauro S ^a   Loveland, Bruce E ^a   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; GAL ANTIGEN; GLYCOLIPID; GLYCOPROTEIN; GLYCOSIDASE; GLYCOSYLTRANSFERASE; MEMBRANE COFACTOR PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BLOOD CLOTTING; CELL NUCLEUS TRANSPLANTATION; COMPLEMENT ACTIVATION; CONFERENCE PAPER; GENETIC ENGINEERING; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KNOCKOUT GENE; MACROPHAGE; MOLECULAR CLONING; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; ORGAN DONOR; T LYMPHOCYTE; TRANSGENICS; XENOTRANSPLANTATION;

EID: 0035575181     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2001.tb00549.x     Document Type: Article

References (94)

1. Galα(1,3)Gal, the major xenoantigen(s) recognized in pigs by human natural antibodies
2. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells
3. Hyperacute renal homograft rejection in man
4. Antipig IgM antibodies in human serum reacts predominantly with Galα(1,3)Gal epitopes
5. Identification of Galα(1,3)Gal as the major epitope for pig-to-human vascularized xenografts
6. Oligosaccharides and discordant xenotransplantation
7. Identification of carbohydrate structures that bind human antiporcine antibodies: Implications for discordant xenografting in humans
8. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human antipig antibodies: Relevance to discordant xenografting in man
9. Characterization of cDNA clones for porcine α1,3 galactosyltransferase: The enzyme generating the Galα(1,3)Gal epitope
10. cDNA sequence and chromosome localization of pig alpha 1,3 galactosyltransferase
11. Isolation of a cDNA encoding a murine UDPgalactose: β-D-galactosyl-1,4-N-acetyl-glucosaminide-α-1,3- galactosyltransferase: Expression cloning by gene transfer
12. Murine α1,3 galactosyltransferase: A single gene locus specifies four isoforms of the enzyme by alternative spicing
13. Bovine α1,3 galactosyltransferase: Lisolation and characterisation of a cDNA clone. Identification of homologous sequences in human genomic DNA
14. Defining the minimal size of catalytically active primate α1,3galactosyltransferase: Structure-function studies on the recombinant truncated enzyme
15. Charac-terization of an α1,3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene
16. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:β-D-Gal 1,4-D- GlcNAcα1,3-galactosyltransferase cDNA
17. Gene sequences suggest inactivation of α,3-galactosyltransferase in catarrhines after divergence of apes from monkeys
18. Gal α(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies
19. Protection of pig kidney (PK15) cells from the cytotoxic effect of antipig antibodies by α-galactosyl oligosaccharides
20. Detection, immunoabsoption, and inhibition of cytotoxic activity of anti-αGal antibodies using newly developed substances with synthetic Gal α1-3Gal disaccharide epitopes
21. Intravenous synthetic αgal saccharides delay hyperacute rejection following pig-to-baboon heart transplantation
22. Intravenous infusion of Gal α1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts
23. In vivo immunoadsorption of antipig antibodies in baboons using a specific Galα1-3Gal column
24. Depletion of anti-Galα1-3Gal antibody in baboons by specific αGal immunoaffinity columns
25. Removal of antiporcine natural antibodies from human and non-human primate plasma in vitro and in vivo by a Galα1-3Galβ1-4βGlc-X immunoaffinity column
26. How important are anti-Gal α(1-3)Gal antibodies in pig to human xenotransplants?
27. Human natural anti-α-galactosyl IgG II. The specific recognition of α(1,3)-linked galactose residues
28. A unique natural human IgG antibody with anti-α-galactosyl specificity
29. Ganglioside xenoantigens in pig lymphocytes and aorta
30. A novel glycosphingolipid expressed in pig kidney: Gal alpha 1-3Lewis(x) hexaglycosylceramide
31. Oocyte Galα1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse
32. The α-1,3-galactosyltransferase knockout mouse: Implications for xenotransplantation
33. Pig cloning by microinjection of fetal fibroblast nuclei
34. Cloned pigs produced by nuclear transfer from adult somatic cells
35. Production of gene-targeted sheep by nuclear transfer from cultured somatic cells
36. Enzymatic remodeling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis
37. Reduction in the level of Gal(α1,3)Gal in transgenic mice and pigs by the expression of an α(1,2)fucosyltransferase
38. Introduction of α(,2)-fucosyltransferase and its effect on α-Gal epitopes in transgenic pig
39. Expression of the human alpha 1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis
40. A murine model for antibody-mediated hyperacute rejection due to anti-Galα(1,3)Gal antibodies in Gal o/o mice
41. Fucosyl transferase (H) transgenic heart transplants to Gal -/-mice
42. Molecular cloning and characterization of the pig secretor type α1,2fucosyltransferase (FUT2)
43. Reduction of the major swine xenoantigen, the α-galactosyl epitope by transfection of the α2,3-sialyltransferase gene
44. Significant down regulation of the major swine xenoantigen by N-acetylglucosaminyltransferase III gene transfection
45. Tetracycline-regulated overexpression of glycosyltransferases in Chinese hamster ovary cells
46. Combined transgenic expression of α-galactosidase and α1,2fucosyltransferase leads to optimal reduction in the major xenoepitope Galα(1,3)Gal
47. Targeting α-galactosidase to the trans golgi network and cell surface
48. Intracellular expression in pig cells of anti-α1,3galactosyltransferase single-chain FV antibodies reduces Gal α1,3Gal expression and inhibits cytotoxicity mediated by anti-Gal xenoantibodies
49. Inhibition of expression of the Galalpha1-3Gal epitope on porcine cells using an intracellular single-chain antibody directed against alpha1,3galactosyltransferase
50. Suppression of porcine xenoantigen expression by dominant-negative effect of alpha-1,3-galactosyltransferase (alpha-1,3-GT) splicing variants
51. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy
52. Mechanism of complement-dependent hemolysis via the lectin pathway: Role of the complement regulatory proteins
53. Knock out of alpha 1,3-galactosyltransferase or expression of alpha 1,2-fucosyltransferase further protects CD55-and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection
54. Factors in xenograft rejection
55. Complement regulatory molecules: Application to therapy and transplantation
56. Regulation of the complement membrane attack pathway
57. Expression of the human alpha1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis
58. Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: The role of thrombin and prostacyclin in hyperacute rejection
59. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts
60. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts
61. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro
62. Inhibition of hyperacute transplant rejection by soluble proteins with the functional domains of CD46 and FcgammaRII
63. Identification and quantitation of complement regulator CD46 on normal human tissues
64. Human membrane cofactor protein (MCP, CD46): Multiple isoforms and functions
65. Human complement regulators: A major target for pathogenic microorganisms
66. Expression and functional analysis of glycosyl-phosphatidyl inositol-linked CD46 in transgenic mice
67. Human CD46 aberrant splicing in transgenic mice
68. Species-specific alternative splicing of transgenic RNA in the mammary glands of pigs, rabbits, and mice
69. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection
70. Functional expression of human CD59 in transgenic mice
71. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium
72. Characterization of pigs transgenic for human decay-accelerating factor
73. Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primates
74. The regulation of membrane cofactor protein (CD46) expression by the 3′ untranslated region in transgenic mice
75. The 3′-UT of the ubiquitous mRNA of human CD46 confers selective suppression of protein production in murine cells
76. Transgenic expression of a CD46 (membrane cofactor protein) minigene: Studies of xenotransplantation and measles virus infection
77. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice
78. Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay accelerating factor
79. Transgenic pigs expressing human CD59 and decay accelerating factor produce an intrinsic barrier to complement-mediated damage
80. Complement-mediated pulmonary xenograft injury: Studies in swine-to-primate orthotopic single lung transplant models
81. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants
82. Mechanism of delayed rejection in transgenic pig-to-primate cardiac xenotransplantation
83. Life-supporting pig-to-baboon heart xenotransplantation
84. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors
85. Xenogeneic endothelial cells activate human prothrombin
86. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor
87. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor
88. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors
89. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF
90. Aggregation of human platelets induced by porcine endothelial cells is dependent upon both activation of complement and thrombin generation
91. Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins
92. Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues
93. Target cell susceptibility to lysis by human natural killer cells is augmented by α(1,3)-galactosyltransferase and reduced by α(1, 2)-fucosyltransferase
94. High-level porcine endothelial cell expression of α(1,2)-fucosyltransferase reduces human monocyte adhesion and activation